Navigation Links
VIVUS to Present at Four Upcoming Investor Conferences in May
Date:4/29/2011

MOUNTAIN VIEW, Calif., April 28, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that VIVUS management will present an overview of the company at four investment conferences during the month of May.  The conference presentation schedule is as follows:Deutsche Bank Health Care ConferenceMay 4, 2011 at 11:20 a.m. ETPresented by: Timothy Morris, chief financial officerInterContinental Boston, Boston, MAJMP Securities 10th Annual Research ConferenceMay 9, 2011 at 9:00 a.m. PTPresented by: Dr. Barbara Troupin, senior director, medical affairsThe Ritz-Carlton, San Francisco, CABank of America Merrill Lynch 2011 Health Care ConferenceMay 11, 2011 at 4:20 p.m. PTPresented by: Peter Tam, presidentEncore Hotel, Las Vegas, NVUBS Global Specialty Pharmaceuticals ConferenceMay 25, 2011 at 2:00 p.m. BSTPresented by: Timothy Morris, chief financial officerUBS, One Finsbury Avenue, London, UKA live audio webcast and 30-day archive of the presentations will be available at http://ir.vivus.com.

About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead product in clinical development, QNEXA, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.

CONTACT: VIVUS, Inc.Investor Relations:The Trout GroupTimothy E. MorrisBrian KorbChief Financial Officer

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. VIVUS Reports First Quarter 2009 Financial Results and Highlights
2. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
3. VIVUS to Present at the Needham and Company Life Sciences Conference
4. VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. VIVUS to Present at Four Upcoming Healthcare Conferences
6. VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
7. VIVUS Reports Third Quarter 2009 Highlights and Financial Results
8. VIVUS to Present at Two Upcoming Investor Conferences
9. VIVUS to Present at Four Upcoming Investor Conferences
10. Data on VIVUS QNEXA to be Presented in Six Posters at The Obesity Societys Annual Meeting
11. VIVUS to Present at the 10th Annual Needham Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 China Biologic ... "Company"), a leading fully integrated plasma-based biopharmaceutical company ... that its majority-owned subsidiary, Shandong Taibang Biological Products ... certification from the China Food and Drug Administration ... facility. As previously disclosed in the Company,s public ...
(Date:12/24/2014)... and NEW YORK , Dec. 23, ... open-label pilot study of mazindol in children with attention ... Therapy in December 2014 . The ... children with attention deficit/hyperactivity disorder" ( Konofal et al, ... Dec 1;8:2321-2332. eCollection 2014 ) shows that mazindol ...
(Date:12/22/2014)... 2014 GenomeDx Biosciences today announced that a ... a genomic test for prostate cancer, was able to ... by radical prostatectomy without adjuvant therapy. Although rapid metastasis ... using tumor genomics to identify these men who have ... important advance. The study has been published online ...
(Date:12/19/2014)... Hershey, PA (PRWEB) December 19, 2014 ... a leading developer and manufacturer of needle-free injection ... an agreement with Immunomic Therapeutics, Inc. (“ITI”) for ... injection device with its LAMP™ vaccine platform. ... for an exclusive Worldwide license to the Biojector®-2000 ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... Tuesday, April 1, 2008 At 10:00 a.m. Eastern ... ... Alseres,Pharmaceuticals, Inc. (Nasdaq: ALSE ) today reported consolidated financial,results for ... http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO ), "2007 was a year of significant ...
... a drug,and diagnostic discovery company, today announced that Matthew ... on April 1st,2008. At the same date, Philippe Rousseau ... CEO is appointed., Philippe Rousseau has served as ... member of its Management Board since 2004. John Jaskowiak,who ...
... Spectros Corporation,(Portola Valley, CA) reported that 2007 year-over-year ... in the hospital for a,broadening array of applications ... was the first device approved by the FDA ... organs receive,insufficient oxygen. "We are pleased that hospitals ...
Cached Biology Technology:Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights 2Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights 3Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights 4Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights 5Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights 6Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights 7Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights 8Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights 9Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights 10ExonHit Appoints a New Management Board 2ExonHit Appoints a New Management Board 3ExonHit Appoints a New Management Board 4Spectros Corporation Reports 2007 Year-Over-Year Sales Rise 36% 2
(Date:12/22/2014)... , Dec. 22, 2014  The 2014 ... the biometrics industry as Acuity Market Intelligence reports ... may finally be open. Acuity forecasts that intensifying ... devices that incorporate biometrics will drive a global ... billion biometric devices by 2020.   ...
(Date:12/19/2014)... 18, 2014  23andMe, Inc., the leading personal genetics ... pinpoints fine-scale differences in genetic ancestry of individuals from ... Since immigrants first arrived more than four hundred ... has served as a meeting place for peoples from ... the ongoing mixing of peoples with African, European, and ...
(Date:12/17/2014)... , Dec. 15, 2014 The ... make it easier to detect and prevent counterfeit ... Today the agency started performing an in-house ... will validate the authenticity of purchased microcircuits while ... new quality control measures will be conducted at ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3
... little water available for plants to grow, their roots ... growth even under water-limiting conditions, according to research published ... University of Milan, Italy in the open access journal ... and soil microbial communities are critical to the health ...
... aerosol particles and the wavelength distribution of incident light ... and cools the local atmosphere, absorbs radiation and warms ... good handle on dust,s primary effect of reflecting and ... absorbing and warming at the longer infrared wavelengths has ...
... more than 1,000 people whose homelands stretch from Africa ... compiled the largest and most detailed catalog yet of ... researchers find the genetic roots of rare and common ... involved some 200 scientists at Washington University School of ...
Cached Biology News:Dust's warming counters half of its cooling effect 2Dust's warming counters half of its cooling effect 3Dust's warming counters half of its cooling effect 4Global genome effort seeks genetic roots of disease 2Global genome effort seeks genetic roots of disease 3